How I treat rituximab refractory patients with WM
Oncotarget
.
2018 Dec 7;9(96):36824-36825.
doi: 10.18632/oncotarget.26411.
Authors
Maria Gavriatopoulou
1
,
Ioannis Ntanasis-Stathopoulos
1
,
Efstathios Kastritis
1
,
Meletios Athanasios Dimopoulos
1
Affiliation
1
Department of Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
PMID:
30627320
PMCID:
PMC6305148
DOI:
10.18632/oncotarget.26411
No abstract available
Keywords:
MYD88; Waldenstrom Macroglobulinemia; ibrutinib; refractory; rituximab.
Publication types
Editorial